OBJECTIVES: We prospectively evaluated procedural costs and resource consumption patterns in the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study after coronary calcium (CAC) measurements. BACKGROUND: Controversy surrounds expansion of cardiovascular disease (CVD) screening to include atherosclerosis imaging as the result of concern whether induced costs will outweigh any benefit. METHODS: Detailed risk factor and CAC measurements with 4-year follow-up for CVD death or myocardial infarction and procedures were performed. Costs were estimated with the use of Medicare reimbursement rates (discounted and inflation corrected). Cox survival analysis was used to estimate procedures and events. RESULTS: CAC scores varied widely but were skewed toward low scores with 56.7% of screened subjects having CAC scores<or=10 and only 8.2% having CAC scores>or=400. Noninvasive testing was infrequent and medical costs were low among subjects with low CAC scores, both rising progressively with increasing CAC scores (p<0.001), particularly in the 31 (2.2% of subjects) that had CAC scores>or=1,000. Similarly, invasive coronary angiography rose progressively with increasing scores (p<0.001) but occurred exclusively among subjects first undergoing noninvasive testing and overall, was performed in only 19.4% of subjects with CAC scores>or=1,000. CONCLUSIONS: CAC scanning is associated with a marked differential in downstream frequency of medical tests and costs, ranging from a very low frequency of testing and invasive procedures among a predominantly large percentage of subjects with low CAC scores, to selectively concentrated testing and procedures among a small number of subjects with CAC scores>400. Thus, CAC scanning appears to foster efficient selective testing patterns among asymptomatic individuals at risk for CVD.
OBJECTIVES: We prospectively evaluated procedural costs and resource consumption patterns in the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study after coronary calcium (CAC) measurements. BACKGROUND: Controversy surrounds expansion of cardiovascular disease (CVD) screening to include atherosclerosis imaging as the result of concern whether induced costs will outweigh any benefit. METHODS: Detailed risk factor and CAC measurements with 4-year follow-up for CVD death or myocardial infarction and procedures were performed. Costs were estimated with the use of Medicare reimbursement rates (discounted and inflation corrected). Cox survival analysis was used to estimate procedures and events. RESULTS: CAC scores varied widely but were skewed toward low scores with 56.7% of screened subjects having CAC scores<or=10 and only 8.2% having CAC scores>or=400. Noninvasive testing was infrequent and medical costs were low among subjects with low CAC scores, both rising progressively with increasing CAC scores (p<0.001), particularly in the 31 (2.2% of subjects) that had CAC scores>or=1,000. Similarly, invasive coronary angiography rose progressively with increasing scores (p<0.001) but occurred exclusively among subjects first undergoing noninvasive testing and overall, was performed in only 19.4% of subjects with CAC scores>or=1,000. CONCLUSIONS: CAC scanning is associated with a marked differential in downstream frequency of medical tests and costs, ranging from a very low frequency of testing and invasive procedures among a predominantly large percentage of subjects with low CAC scores, to selectively concentrated testing and procedures among a small number of subjects with CAC scores>400. Thus, CAC scanning appears to foster efficient selective testing patterns among asymptomatic individuals at risk for CVD.
Authors: Jacobo Kirsch; Ivan Buitrago; Tan-Lucien H Mohammed; Tianming Gao; Craig R Asher; Gian M Novaro Journal: Int J Cardiovasc Imaging Date: 2011-08-11 Impact factor: 2.357
Authors: Michael G Silverman; James R Harkness; Ron Blankstein; Matthew J Budoff; Arthur S Agatston; J Jeffrey Carr; Joao A Lima; Roger S Blumenthal; Khurram Nasir; Michael J Blaha Journal: JACC Cardiovasc Imaging Date: 2014-05
Authors: Leslee J Shaw; Abhinav Goyal; Christina Mehta; Joe Xie; Lawrence Phillips; Anita Kelkar; Joseph Knapper; Daniel S Berman; Khurram Nasir; Emir Veledar; Michael J Blaha; Roger Blumenthal; James K Min; Reza Fazel; Peter W F Wilson; Matthew J Budoff Journal: J Am Coll Cardiol Date: 2018-03-13 Impact factor: 24.094
Authors: Frederic Commandeur; Piotr J Slomka; Markus Goeller; Xi Chen; Sebastien Cadet; Aryabod Razipour; Priscilla McElhinney; Heidi Gransar; Stephanie Cantu; Robert J H Miller; Alan Rozanski; Stephan Achenbach; Balaji K Tamarappoo; Daniel S Berman; Damini Dey Journal: Cardiovasc Res Date: 2020-12-01 Impact factor: 10.787
Authors: Seth Uretsky; Alan Rozanski; Padmakshi Singh; Azhar Supariwala; Prashanth Atluri; Sripal Bangalore; Thomas W Pappas; Edward A Fisher; M Robert Peters Journal: Int J Cardiovasc Imaging Date: 2010-10-22 Impact factor: 2.357
Authors: Philip Greenland; Michael J Blaha; Matthew J Budoff; Raimund Erbel; Karol E Watson Journal: J Am Coll Cardiol Date: 2018-07-24 Impact factor: 24.094
Authors: Michael J Blaha; Matthew J Budoff; Andrew P DeFilippis; Ron Blankstein; Juan J Rivera; Arthur Agatston; Daniel H O'Leary; Joao Lima; Roger S Blumenthal; Khurram Nasir Journal: Lancet Date: 2011-08-20 Impact factor: 79.321
Authors: Alan Rozanski; Heidi Gransar; Leslee J Shaw; Johanna Kim; Lisa Miranda-Peats; Nathan D Wong; Jamal S Rana; Raza Orakzai; Sean W Hayes; John D Friedman; Louise E J Thomson; Donna Polk; James Min; Matthew J Budoff; Daniel S Berman Journal: J Am Coll Cardiol Date: 2011-04-12 Impact factor: 24.094
Authors: Michael D Miedema; Daniel A Duprez; Jeffrey R Misialek; Michael J Blaha; Khurram Nasir; Michael G Silverman; Ron Blankstein; Matthew J Budoff; Philip Greenland; Aaron R Folsom Journal: Circ Cardiovasc Qual Outcomes Date: 2014-05-06